{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-001679","form_type":"8-K","ticker":"CAMP","cik":"0001736730","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.664556+00:00","generated_at":"2026-05-28T08:47:34.852277+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Camp4 Therapeutics reports positive Phase 1 SAD safety data for CMP-CPS-001, enables MAD dose escalation","bullets":["Phase 1 SAD portion completed: 48 healthy volunteers, 32 received CMP-CPS-001; no serious adverse events, no maximum tolerated dose reached.","All treatment-emergent adverse events were Grade 1 or 2; most common: headache (6), nausea (4).","Safety Review Committee approved dose escalation and initiation of MAD Cohort 3.","Cash runway into Q2 2026; upcoming milestones: MAD data 2H'25, SYNGAP1 GLP tox studies in '25.","Corporate slide deck highlights RAP platform, pipeline, and strategic collaboration; IPO completed October 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-001679","json":"https://secwatch.observer/filing/0001104659-25-001679.json","markdown":"https://secwatch.observer/filing/0001104659-25-001679.md","text":"https://secwatch.observer/filing/0001104659-25-001679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736730/000110465925001679/0001104659-25-001679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736730/000110465925001679/tm252128d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T08:47:34.852277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}